Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

Investor Overview

Investor Overview

Corporate Profile

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

News Releases

Date Title and Summary Additional Formats
Toggle Summary Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
– Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.61 and Non-GAAP Earnings per Share of $2.01 – – Full-Year GAAP Earnings per Share of $5.07 and Non-GAAP Earnings per Share of $6.73 – – Provides 2020 Guidance –
View HTML
Toggle Summary Charles River Laboratories Schedules Fourth-Quarter 2019 Earnings and 2020 Guidance Release and Conference Call
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 21, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2019 financial results and provide 2020 guidance on Tuesday, February 11 th , before the market opens.
View HTML
Toggle Summary Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment
Together, Charles River and Fios Genomics aim to accelerate preclinical discovery and development by turning complex data into actionable information WILMINGTON, Mass. & EDINBURGH, Scotland --(BUSINESS WIRE)--Jan. 16, 2020-- Charles River Laboratories International, Inc.
View HTML
Toggle Summary Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates
The integrated drug discovery collaboration will focus on Takeda’s four core therapeutic areas WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 13, 2020-- Charles River (NYSE: CRL) today announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”).
View HTML
Upcoming Events
There are currently no events scheduled.